The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial.

DD01 significantly reduces liver fat by at least 30% in 76% of adults with MASH or MASLD after 12 weeks, outperforming placebo in a phase 2 trial.

• Why it matters: Effective treatments for metabolic dysfunction-associated steatohepatitis are limited, and early liver fat reduction could prevent disease progression and improve patient outcomes.
• What they did: A 12-week, randomized, double-blind, placebo-controlled trial involving 67 adults with obesity and liver disease assessed DD01, a dual GLP-1 and glucagon receptor agonist, measuring liver fat reduction via MRI-PDFF.
• The result: DD01 led to rapid, substantial liver fat reduction with acceptable safety, indicating its potential as a promising therapy for MASH and MASLD, warranting further long-term studies.